What Abogen Biosciences does

Abogen Biosciences (Suzhou Abogen Biosciences Co., Ltd., 苏州艾博生物科技有限公司) is a privately held, clinical-stage biotechnology company founded in January 2019 and headquartered in Suzhou Industrial Park, China, with additional offices in Wuxi, Shanghai, and Beijing and approximately 251–500 employees. The company develops nucleic acid-based therapeutics and vaccines built on a proprietary xRNA technology platform that spans three RNA modalities — linear mRNA, circular RNA (via its Cis-System), and self-amplifying RNA (saRNA) — paired with a proprietary Lipid Nanoparticle (LNP) delivery system, a proprietary nucleoside base modification that bypasses m1Ψ patent barriers, and a lyophilized formulation enabling 2–8°C stability for 2–3 years. Core technology infrastructure includes dynamic precision mixing for LNP encapsulation (>90% efficiency), AI-driven ionizable lipid design, miRNA-responsive circRNA expression, and a protein structure design platform for antigen optimization.

The company's pipeline addresses three primary therapeutic verticals: infectious disease (ARCoV/AWcorna COVID-19 vaccine — EUA in Indonesia; ABO1108 lyophilized shingles vaccine in Phase III as the world's first mRNA shingles candidate in Phase III; RSV vaccine with NMPA IND; a nasal-spray TB vaccine co-developed with Malaysia's UKM), oncology/immuno-oncology (ABO2203 mRNA-encoded CD3×CD19 T-cell engager with 100% ORR in high-dose Phase 1 cohort for R/R B-NHL; ABO2102 multi-KRAS mRNA cancer vaccine with dual China/U.S. IND), and autoimmune disease (mRNA-encoded bispecific antibodies for B-cell depletion), with a secondary protein-replacement therapy segment. Platform-level LNP safety has been validated in 30,000+ Phase III participants globally across Indonesia, UAE, and the Philippines.

Abogen's revenue model combines three streams: vaccine product sales (primarily through the Indonesia EUA and government-channel distribution), asset out-licensing of regional or global rights to pipeline programs in infectious disease and oncology, and platform technology licensing for partners developing genetic medicines on the xRNA/LNP stack. Commercial pricing is not publicly disclosed. The company has raised over $1.1 billion across Series A (RMB 150M, Oct 2020), Series B (RMB 600M, Apr 2021), Series C ($700M+, Aug 2021, led by Temasek/Invesco), and Series C+ ($300M, Nov 2021, led by SoftBank Vision Fund). Strategic partnerships include PT Etana Biotechnologies Indonesia (manufacturing technology transfer), PLA Academy of Military Sciences and Walvax Biotechnology (COVID-19 co-development), and Ruijin Hospital (oncology/autoimmune research institute). The company remains pre-revenue commercially and is led by Founder/Chairman/CEO Dr. Bo Ying.

Name

Abogen Biosciences

Legal name

Suzhou Abogen Biosciences Co., Ltd.

Website

https://abogenbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Abogen Biosciences is a clinical-stage Chinese biotech developing mRNA, circRNA, and saRNA therapeutics and vaccines across infectious disease, oncology, and autoimmune indications, using a proprietary LNP delivery platform validated in 30,000+ trial participants, with one COVID-19 vaccine authorized in Indonesia and a shingles vaccine now in Phase III.

Ownership category

akta.pro rank

Product category

mRNA Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• MRNA vaccines
• Nucleic acid therapeutics
• Lipid nanoparticle delivery
• Cancer immunotherapy
• Infectious disease vaccines

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Vaccine Product Sales: Revenue from sale of mRNA vaccine products including COVID-19 vaccine (ARCoV/AWcorna) and pipeline vaccines for infectious diseases. Currently commercialized in Indonesia under EUA with manufacturing license obtained November 2021.
2. Asset Out-licensing: Licensing of global or regional rights of pipeline assets including infectious disease and cancer vaccines as well as protein replacement therapy for autoimmune diseases.
3. Platform Technology Licensing: Research collaborations with companies utilizing Abogen's end-to-end technology platform to develop genetic medicines.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

Abogen Biosciences is a clinical-stage biotechnology company that develops mRNA-based vaccines and therapeutics for infectious diseases, oncology, and autoimmune disorders. Its integrated offering covers an end-to-end xRNA platform spanning linear mRNA, circular RNA (circRNA), and self-amplifying RNA (saRNA) technologies paired with a proprietary lipid nanoparticle (LNP) delivery system and AI-driven design capabilities. The company's pipeline includes a COVID-19 vaccine authorized in Indonesia, a lyophilized mRNA shingles vaccine in Phase III, a KRAS mRNA cancer vaccine with dual IND approvals, an RSV vaccine, and CD3×CD19 T-cell engager for B-cell non-Hodgkin lymphoma.

Product overview

Abogen Biosciences is a clinical-stage biotech company offering an integrated mRNA drug development platform and pipeline of mRNA-based vaccines and therapeutics. The core offering is the xRNA Platform covering mRNA, circRNA, and saRNA technologies, complemented by a proprietary LNP delivery system and AI-driven design capabilities. Key products include: ARCoV/AWcorna COVID-19 vaccine (EUA in Indonesia), ABO2203 CD3×CD19 T-cell engager for NHL, ABO2102 KRAS mRNA cancer vaccine (dual IND approved), ABO1108 shingles vaccine (Phase III), lyophilized RSV vaccine (IND approved), and a nasal spray TB vaccine (National Key R&D Program). The company provides end-to-end capabilities from mRNA design through GMP manufacturing, with formulation options including liquid, lyophilized, and frozen formats.

Differentiator

Problem solved

Functional benefit

Brands

• AWcorna: Commercial brand name for Abogen's COVID-19 mRNA vaccine ARCoV that received Emergency Use Authorization in Indonesia.

Products and services

• ARCoV/AWcorna COVID-19 mRNA Vaccine mRNA COVID-19 vaccine co-developed with the PLA Academy of Military Sciences and Walvax Biotechnology; received Emergency Use Authorization in Indonesia in September 2022, becoming China's first internationally approved mRNA vaccine for primary and booster immunization in adults.
• ABO2102 KRAS mRNA Cancer Vaccine Therapeutic mRNA cancer vaccine encoding five common KRAS-mutant antigens to activate CD8+ cytotoxic T cells and CD4+ helper T cells against solid tumors; received dual IND approval from China NMPA and U.S. FDA in 2025.
• ABO1108 Lyophilized mRNA Shingles Vaccine Lyophilized mRNA vaccine for herpes zoster (shingles) using a structurally optimized gE protein antigen design with proprietary nucleoside base modification and LNP delivery; world's first mRNA shingles vaccine to enter Phase III clinical development.
• Lyophilized RSV mRNA Vaccine Respiratory syncytial virus mRNA vaccine employing proprietary nucleoside base modification technology and a patented LNP delivery system, with lyophilized formulation maintaining stability for over two years at 2-8°C.
• ABO2203 mRNA-Encoded CD3×CD19 T-cell Engager

Quantifiable outcome

• 100% objective response rate in high-dose cohort of ABO2203 Phase 1 trial for R/R B-NHL
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Partnerships

Six partnerships are on record, tiered flagship and core.

• National University of Malaysia (UKM)flagshipStrategic or Co-development Partner · 1 January 2025Joint project under China's National Key R&D Programme to develop nasal spray mRNA tuberculosis vaccine using mucosal-anchored adjuvant nanoparticle delivery technology. Combines Abogen's ionizable lipid library validated in 30,000+ participants with UKM's specialized MARE mucosal-anchored adjuvant LNP platform.
• Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of MedicineflagshipStrategic or Co-development Partner · 1 June 2024Jointly established Ruijin-Abogen Nucleic Acid Drug Research Institute for clinical translation of mRNA drugs in oncology and autoimmune diseases. Multiple projects已进入 investigator-initiated clinical trials (IIT) covering lung cancer, pancreatic cancer, and colorectal cancer.
• PT Etana Biotechnologies IndonesiaflagshipStrategic or Co-development Partner · 1 July 2022Manufacturing partnership to build mRNA vaccine production facility in Indonesia through technology transfer. Factory will be first of its kind in Southeast Asia, equipped with capabilities for pandemic response and access to Abogen's expanding portfolio of mRNA therapeutic products.
• People's Liberation Army (PLA) Academy of Military SciencescoreStrategic or Co-development PartnerCo-development partner for COVID-19 mRNA vaccine development. Military research institution collaborating on vaccine research and development.
• Walvax Biotechnology Co., Ltd.coreStrategic or Co-development PartnerCo-development partner for COVID-19 mRNA vaccine ARCoV. Collaborated on vaccine development, clinical trials, and manufacturing.
• WHO/MPP mRNA Technology Transfer ProgrammeflagshipStrategic or Co-development PartnerParticipation in WHO and Medicines Patent Pool initiative for global mRNA technology transfer to enhance equitable access to mRNA vaccines worldwide.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• BioNTech: Global mRNA therapeutics leader (Comirnaty COVID-19 vaccine with Pfizer; oncology pipeline). Directly comparable to Abogen as a pure-play mRNA platform company pursuing infectious disease vaccines and oncology therapeutics, with overlapping modality (mRNA + LNP) and target indications.
• Moderna: Global mRNA therapeutics leader with approved COVID-19, RSV, and flu vaccines plus an oncology and rare disease pipeline. Most directly comparable mRNA peer; Abogen's Chief AI Officer (Dr. McFadyen) is a former Moderna VP who built its computational science function.
• Stemirna Therapeutics: Chinese clinical-stage mRNA biotech developing COVID-19, infectious disease, and oncology vaccines using mRNA and LNP platforms. Closest head-to-head Chinese competitor to Abogen with similar platform technology, target indications, and China-based regulatory pathway.
• CureVac: German mRNA therapeutics company developing prophylactic vaccines, oncology, and protein replacement therapies. Comparable modality (mRNA platform with proprietary delivery) and similar clinical-stage positioning, with overlapping focus on infectious disease and oncology.
• Arcturus Therapeutics: US clinical-stage mRNA company with self-amplifying RNA (saRNA) platform and LNP delivery system. Directly comparable to Abogen's xRNA platform (mRNA/circRNA/saRNA) and pursues similar infectious disease and rare disease indications with comparable clinical-stage profile.
• CanSino Biologics: Chinese vaccine developer with approved viral-vector COVID-19 vaccine and expanding mRNA pipeline. Comparable as a leading Chinese vaccine innovator pursuing both viral vector and mRNA modalities for infectious disease, with similar target markets and regulatory pathways.
• Walvax Biotechnology: Chinese vaccine manufacturer and Abogen's co-development partner on the ARCoV COVID-19 mRNA vaccine. Comparable as a Chinese mRNA vaccine developer/manufacturer with overlapping pipeline and similar distribution focus on domestic and emerging markets.

Broad incumbents

• Sanofi Pasteur: Global vaccines business of Sanofi with established franchises in influenza, pediatric, and travel vaccines; actively expanding into mRNA through Translate Bio acquisition and internal programs. Broad incumbent competitor in infectious disease vaccines that Abogen's mRNA platform aims to disrupt.
• GSK Vaccines: Major global vaccines business with established shingles (Shingrix), hepatitis, and pediatric vaccine franchises. Directly relevant incumbent for the shingles vaccine market that Abogen's ABO1108 Phase III mRNA candidate targets.
• CSPC Pharmaceutical Group: Large Chinese pharmaceutical conglomerate with growing mRNA vaccine and biologics pipeline. Comparable as a major Chinese pharma pursuing mRNA and other modalities for infectious disease and oncology, providing context on domestic scale and competition.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors39 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abogen Biosciences